A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
Overview
- Phase
- Phase 3
- Intervention
- Aripiprazole
- Conditions
- Bipolar I Disorder
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Enrollment
- 99
- Primary Endpoint
- Young Mania Rating Scale (YMRS)
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
To investigate the safety and efficacy of long-term administration of aripiprazole by performing extended administration of the treatment administered in the preceding multicenter, double-blind, placebo-controlled, parallel group-comparison trial of aripiprazole in patients with bipolar disorder experiencing a manic or mixed episode (Study 031-06-003, hereafter "Study 003") in a double-blind manner to those patients who complete Study 003 and demonstrate drug efficacy.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Trial subjects will be men and women of age 18 or above and below the age of 65 who will not be turning 65 during the trial.
- •Subjects have the ability to understand and to provide informed consent to the examination, observation, and evaluation processes specified in this protocol, and have signed the informed consent form based on a full understanding of the trial.
- •Subjects who meet DSM-IV-TR criteria for manic or mixed episodes and have been diagnosed as having "296.4x Bipolar I Disorder in which the most recent episode was manic" or "296.6x Bipolar I Disorder in which the most recent episode was mixed"
- •Subjects who were enrolled in and have completed Study 003 and who meet the following criteria for demonstration of drug efficacy
- •Subjects demonstrating drug efficacy:
- •Those subjects who completed Study 003 whose score for CGI-BP Change From Preceding Phase (mania) at the time of evaluation on Day 21 of Study 003 (completion) was between 1 (Very much improved) and 3 (Minimally improved)
Exclusion Criteria
- •Subjects presenting with a clinical picture and/or history that is consistent with a DSM-IV-TR diagnosis of:
- •Delirium, dementia, amnestic disorder, or other cognitive disorders
- •Schizophrenia or other psychotic disorder
- •Personality disorder
- •Subjects with psychotic symptoms that are clearly due to another general medical condition or direct physiological effects of a substance
- •Subjects who represent a significant risk of committing suicide
- •Subjects known to have a complication of allergy to aripiprazole or other quinolinone-skeleton compounds
- •Subjects with a complication of neuroleptic malignant syndrome
- •Subjects in a state of physical exhaustion accompanied by such conditions as dehydration or malnutrition
- •Subjects with a complication of paralytic ileus
Arms & Interventions
1
Intervention: Aripiprazole
2
Intervention: placebo
Outcomes
Primary Outcomes
Young Mania Rating Scale (YMRS)
Time Frame: Baseline (Day 1 of preceding study) , Day 154 or at discontinuation
Using LOCF datasets, descriptive statistics of actual values for changes of YMRS total scores from baseline (Day 1 of preceding study) to endpoint (Day 154) was calculated for each treatment group. YMRS is composed of 11 evaluation items with 5 rating levels each. Items rated on a scale of 0 to 4 (comprising 5 rating levels of one point each) are 1) levated mood, 2) increased motor activity/energy, 3) sexual interest, 4) sleep, 7) language-thought disorder, 10) appearance, and 11) insight. Items rated on a scale of 0 to 8 (comprising 5 rating levels of two points each) are 5) irritability, 6) speech (rate and amount), 8) content, and 9) disruptive-aggressive behavior. YMRS ranges from 0 (best possible outcome) to 60 (worst possible outcome).
Secondary Outcomes
- Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness (Mania)(Baseline (Day 1 of preceding study), Day 154 or at discontinuation)